Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic. Issue 1 (19th November 2021)

• Record Type: Journal Article
• Authors: Avenoso, Daniele; Milojkovic, Dragana; Clark, James; Pocock, Christopher; Potter, Victoria; Yallop, Deborah; Hannah, Guy
• Is Part Of: EJHaem. Volume 3:Issue 1(2022)
• Page Start: 215
• Page End: 217
• Publication Date: 2021-11-19
• Subjects: CML -- COVID‐19 -- sudden blast crisis -- TRF; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.302
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: During the COVID‐19 pandemic, access to health services has been considerably restricted and furthermore, patients have been reluctant to attend for routine monitoring, and this may have had a negative impact in the management of patients affected with haematological disorders. Sudden blast crisis in chronic myeloid leukaemia is categorized as a rapid onset of blastic phase, after a documented 'optimal' response to tyrosine kinase inhibitor (TKI) therapy and within 3 months of a normal complete blood count. Herein, we describe a case of patient who developed sudden blast crisis after TKI while in treatment‐free remission.